These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30105474)

  • 1. Phencyclidine-Based New Psychoactive Substances.
    Wallach J; Brandt SD
    Handb Exp Pharmacol; 2018; 252():261-303. PubMed ID: 30105474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances.
    Wallach J; Brandt SD
    Handb Exp Pharmacol; 2018; 252():305-352. PubMed ID: 30196446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phencyclidine analog use in Sweden--intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project.
    Bäckberg M; Beck O; Helander A
    Clin Toxicol (Phila); 2015 Nov; 53(9):856-64. PubMed ID: 26295489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues.
    Colestock T; Wallach J; Mansi M; Filemban N; Morris H; Elliott SP; Westphal F; Brandt SD; Adejare A
    Drug Test Anal; 2018 Feb; 10(2):272-283. PubMed ID: 28513099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.
    Morris H; Wallach J
    Drug Test Anal; 2014; 6(7-8):614-32. PubMed ID: 24678061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detectability of Dissociative Psychoactive Substances in Urine by Five Commercial Phencyclidine Immunoassays.
    Gomila I; Leciñena MÁ; Elorza MÁ; Pastor Y; Sahuquillo L; Servera M; Puiguriguer J; Barcelo B
    J Anal Toxicol; 2019 Jul; 43(6):497-503. PubMed ID: 31329888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties.
    Swedberg MD; Ellgren M; Raboisson P
    J Pharmacol Exp Ther; 2014 Apr; 349(1):155-64. PubMed ID: 24472725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists.
    French ED; Mura A; Wang T
    Synapse; 1993 Feb; 13(2):108-16. PubMed ID: 8446919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two Fatal Intoxications Involving 3-Methoxyphencyclidine.
    Mitchell-Mata C; Thomas B; Peterson B; Couper F
    J Anal Toxicol; 2017 Jul; 41(6):503-507. PubMed ID: 28830118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of emerging and new psychoactive substances in the United Kingdom.
    Beharry S; Gibbons S
    Forensic Sci Int; 2016 Oct; 267():25-34. PubMed ID: 27552699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the inhibition of excitatory amino acid-induced neurotransmitter release in the rat striatum by phencyclidine-like drugs.
    Snell LD; Johnson KM
    J Pharmacol Exp Ther; 1986 Sep; 238(3):938-46. PubMed ID: 2875174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DARK Classics in Chemical Neuroscience: Phencyclidine (PCP).
    Bertron JL; Seto M; Lindsley CW
    ACS Chem Neurosci; 2018 Oct; 9(10):2459-2474. PubMed ID: 29953199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats.
    Nicholson KL; Balster RL
    Psychopharmacology (Berl); 2003 Nov; 170(2):215-24. PubMed ID: 12851738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat.
    Klamer D; Zhang J; Engel JA; Svensson L
    Behav Brain Res; 2005 Apr; 159(1):95-103. PubMed ID: 15795002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines.
    Wallach J; Colestock T; Cicali B; Elliott SP; Kavanagh PV; Adejare A; Dempster NM; Brandt SD
    Drug Test Anal; 2016 Aug; 8(8):801-15. PubMed ID: 26360516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designer drugs: a medicinal chemistry perspective.
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of emerging new psychoactive substances: The first fatal 3-MeO-PCP intoxication in The Netherlands.
    de Jong LAA; Olyslager EJH; Duijst WLJM
    J Forensic Leg Med; 2019 Jul; 65():101-104. PubMed ID: 31129558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects.
    Pelletier R; Le Daré B; Le Bouëdec D; Kernalléguen A; Ferron PJ; Morel I; Gicquel T
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
    Zawilska JB; Andrzejczak D
    Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective depression of the segmental polysynaptic reflex by phencyclidine and its analogs in the rat in vitro: interaction with N-methyl-D-aspartate receptors.
    Ohno Y; Warnick JE
    J Pharmacol Exp Ther; 1990 Jan; 252(1):246-52. PubMed ID: 1967645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.